Anti-Occludin Antibody, clone 1C17 ZooMAb^® Rabbit Monoclonal

rabbit (recombinant)

expressed in HEK 293 cells

unconjugated

purified antibody

primary antibodies

1C17, monoclonal
recombinant monoclonal

ZooMAb^® learn more

lyophilized

calculated mol wt 59.14 kDa
observed mol wt 55 kDa

canine, human

antibody small pack of 25 μL

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

recombinant expression
Learn more about Antibody Enhanced Validation

affinity binding assay: suitable
immunocytochemistry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable

IgG

Aligned

ambient

2-8℃

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Clone 1C17 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Occludin. It targets an epitope within 113 amino acids from the C-terminal region.

GST/His-tagged recombinant fragment corresponding to 113 amino acids from the C-terminal region of human Occludin.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Occludin in HEK 293 cells.

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected Occludin in human kidney tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound recombinant human Occludin with a KD of 1.1 x 10-7 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Anti-Occludin, clone 1C17 ZooMAb, Cat. No. ZRB1451, is a recombinant Rabbit monoclonal antibody that targets Occludin and is tested for use in Affinity Binding Assay, Immunocytochemistry, and Immunohistochemistry (Paraffin), and Western Blotting.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

0.3 mg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Occludin (UniProt: Q16625; also known as OCLN) is encoded by the OCLN gene (Gene ID: 100506658) in human. Occludin is a multi-pass membrane protein that localizes at tight junctions of both epithelial and endothelial cells. It is shown to be highly expressed in kidneys. It plays a role in the formation and regulation of the tight junction paracellular permeability barrier and prevents the transport of macromolecules through the tight junction. Dysregulation of occlude leads to several diseases, including cancer, stroke, and inflammatory lung disease. Occludin has two extracellular domains (aa 90-135 and 196-243), four transmembrane domains (aa 67-89, 136-160, 171-195, and 244-265), and three cytoplasmic domains (aa 1-66, 161-170, and 266-522). The C-terminal cytoplasmic tail binds directly to the ZO-1 proteins, which links the protein complex to the actin cytoskeleton and is involved in the regulation of the permeability barrier function of tight junctions. The first extracellular loop participates in an adhesive interaction. Occludin also exhibits a MARVEL domain (aa 60-269) that is involved in membrane apposition and fusion events. Overexpression of occludin in Madin-Darby canine kidney (MDCK) cells is reported to enhance transepithelial electrical resistance in these cells. Reversible phosphorylation of occluding is shown to play a major role in regulation of occludin and it is tight junction barrier properties. Mutations in OCLN gene can cause Pseudo-TORCH syndrome that is Characterized by microcephaly, intracranial calcifications, and severe developmental delays. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Cummins, PM (2012). Mol. Cell Biol. 32(2): 242-250).

Recommend storage of lyophilized product at 2-8℃; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8℃, or -20℃ for long term storage. Avoid repeated freeze-thaws.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

11 - Combustible Solids

WGK 1